Reply to: Can circulating CD34+ cells count be used for the prognosis of myelofibrosis? Probably yes, at least in patients treated with ruxolitinib

Br J Haematol. 2023 Mar;200(6):e53-e55. doi: 10.1111/bjh.18641. Epub 2023 Jan 4.

Authors

Alessandra Iurlo¹, Nicole Galli^{1

2}, Cristina Bucelli¹, Silvia Artuso¹, Dario Consonni³, Daniele Cattaneo^{1

2}

Affiliations

¹ Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
² Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
³ Epidemiology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

PMID: 36600586
DOI: 10.1111/bjh.18641

No abstract available

Keywords: CD34+; myelofibrosis; prognosis; ruxolitinib.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Nitriles
Primary Myelofibrosis*
Prognosis
Pyrimidines

Substances

ruxolitinib
Nitriles
Pyrimidines